中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2013年
4期
320-326
,共7页
许艳%赵旭%张丰菊%王萌萌%郭宁%郑燕%柳静%张秋露
許豔%趙旭%張豐菊%王萌萌%郭寧%鄭燕%柳靜%張鞦露
허염%조욱%장봉국%왕맹맹%곽저%정연%류정%장추로
二苯甲酮类%溴化苯类%眼药水%氟米龙%角膜磨镶术,激光原位%激光,准分子%治疗结果
二苯甲酮類%溴化苯類%眼藥水%氟米龍%角膜磨鑲術,激光原位%激光,準分子%治療結果
이분갑동류%추화분류%안약수%불미룡%각막마양술,격광원위%격광,준분자%치료결과
Benzophenones%Bromobenzenes%Ophthalmic solutions%Fluorometholone%Keratomileusis,laser in situ%Lasers,excimer%Treatment outcome
目的 探讨近视散光眼行前弹力层下准分子激光原位角膜磨镶术(SBK)后应用0.1％溴芬酸钠水合物滴眼液的疗效及安全性.方法 采用病例对照研究,中低度近视眼患者(-6.00 D≤等效球镜＜-2.00 D)试验组和对照组分别为17例(32只眼)和20例(40只眼),高度近视眼患者(-11.00 D≤等效球镜＜-6.00 D)试验组和对照组分别为22例(42只眼)和15例(26只眼).试验组SBK术后第1天开始使用0.1％溴芬酸钠水合物滴眼液,中低度近视眼患者持续10 d,高度近视眼患者持续14d；对照组术后第1天开始使用0.1％氟米龙滴眼液,持续16d.术后不同时间分别对患者进行裸眼视力、电脑验光、眼压和角膜地形图检查,术后每次随访记录患者眼部症状及相关并发症.计量资料采用独立样本t检验,等级资料采用秩和检验进行统计学分析.结果 中低度近视眼患者术后1个月、3个月眼压均值试验组分别为(7.84±1.35)和(8.13±1.75)mm Hg(1 mm Hg=0.133 kPa),对照组分别为(9.37±1.28)和(9.47±1.58)mm Hg,差异均有统计学意义(t=-3.244,-3.336;P ＜0.05)；角膜曲率K2均值试验组分别为(38.66±1.68)和(38.75±1.45)D,对照组分别为(39.56±1.58)和(39.51±1.50)D,试验组均低于对照组,差异具有统计学意义(t=-2.299,-2.112；P＜0.05)；术后ld、7d、1个月、3个月、6个月两组间平均裸眼视力(t=-1.240,-1.917,-0.596,-1.394,-0.329)、等效球镜(t=0.054,0.222,0.936,-0.141,0.336)和术后1、3、6个月平均角膜曲率Kl(t=-1.695,-1.492,-0.438)和散光CY(t=0.879,0.733,0.553)及术后6个月平均眼压(t=-1.225)、角膜曲率K2(t=-0.727)差异均无统计学意义(P＞0.05).高度近视患者术后3个月裸眼视力均值试验组和对照组分别为5.14 ±0.06、5.09 ±0.07,差异具有统计学意义(t =2.517,P=0.015).两组患者间各主观症状相似；所有患者均未出现高眼压及屈光度数明显回退现象.结论 SBK术后应用0.1％溴芬酸钠水合物滴眼液可以达到与氟米龙滴眼液同样的治疗效果,在术后眼压安全性方面0.1％溴芬酸钠水合物滴眼液更优于氟米龙滴眼液.
目的 探討近視散光眼行前彈力層下準分子激光原位角膜磨鑲術(SBK)後應用0.1％溴芬痠鈉水閤物滴眼液的療效及安全性.方法 採用病例對照研究,中低度近視眼患者(-6.00 D≤等效毬鏡＜-2.00 D)試驗組和對照組分彆為17例(32隻眼)和20例(40隻眼),高度近視眼患者(-11.00 D≤等效毬鏡＜-6.00 D)試驗組和對照組分彆為22例(42隻眼)和15例(26隻眼).試驗組SBK術後第1天開始使用0.1％溴芬痠鈉水閤物滴眼液,中低度近視眼患者持續10 d,高度近視眼患者持續14d；對照組術後第1天開始使用0.1％氟米龍滴眼液,持續16d.術後不同時間分彆對患者進行裸眼視力、電腦驗光、眼壓和角膜地形圖檢查,術後每次隨訪記錄患者眼部癥狀及相關併髮癥.計量資料採用獨立樣本t檢驗,等級資料採用秩和檢驗進行統計學分析.結果 中低度近視眼患者術後1箇月、3箇月眼壓均值試驗組分彆為(7.84±1.35)和(8.13±1.75)mm Hg(1 mm Hg=0.133 kPa),對照組分彆為(9.37±1.28)和(9.47±1.58)mm Hg,差異均有統計學意義(t=-3.244,-3.336;P ＜0.05)；角膜麯率K2均值試驗組分彆為(38.66±1.68)和(38.75±1.45)D,對照組分彆為(39.56±1.58)和(39.51±1.50)D,試驗組均低于對照組,差異具有統計學意義(t=-2.299,-2.112；P＜0.05)；術後ld、7d、1箇月、3箇月、6箇月兩組間平均裸眼視力(t=-1.240,-1.917,-0.596,-1.394,-0.329)、等效毬鏡(t=0.054,0.222,0.936,-0.141,0.336)和術後1、3、6箇月平均角膜麯率Kl(t=-1.695,-1.492,-0.438)和散光CY(t=0.879,0.733,0.553)及術後6箇月平均眼壓(t=-1.225)、角膜麯率K2(t=-0.727)差異均無統計學意義(P＞0.05).高度近視患者術後3箇月裸眼視力均值試驗組和對照組分彆為5.14 ±0.06、5.09 ±0.07,差異具有統計學意義(t =2.517,P=0.015).兩組患者間各主觀癥狀相似；所有患者均未齣現高眼壓及屈光度數明顯迴退現象.結論 SBK術後應用0.1％溴芬痠鈉水閤物滴眼液可以達到與氟米龍滴眼液同樣的治療效果,在術後眼壓安全性方麵0.1％溴芬痠鈉水閤物滴眼液更優于氟米龍滴眼液.
목적 탐토근시산광안행전탄력층하준분자격광원위각막마양술(SBK)후응용0.1％추분산납수합물적안액적료효급안전성.방법 채용병례대조연구,중저도근시안환자(-6.00 D≤등효구경＜-2.00 D)시험조화대조조분별위17례(32지안)화20례(40지안),고도근시안환자(-11.00 D≤등효구경＜-6.00 D)시험조화대조조분별위22례(42지안)화15례(26지안).시험조SBK술후제1천개시사용0.1％추분산납수합물적안액,중저도근시안환자지속10 d,고도근시안환자지속14d；대조조술후제1천개시사용0.1％불미룡적안액,지속16d.술후불동시간분별대환자진행라안시력、전뇌험광、안압화각막지형도검사,술후매차수방기록환자안부증상급상관병발증.계량자료채용독립양본t검험,등급자료채용질화검험진행통계학분석.결과 중저도근시안환자술후1개월、3개월안압균치시험조분별위(7.84±1.35)화(8.13±1.75)mm Hg(1 mm Hg=0.133 kPa),대조조분별위(9.37±1.28)화(9.47±1.58)mm Hg,차이균유통계학의의(t=-3.244,-3.336;P ＜0.05)；각막곡솔K2균치시험조분별위(38.66±1.68)화(38.75±1.45)D,대조조분별위(39.56±1.58)화(39.51±1.50)D,시험조균저우대조조,차이구유통계학의의(t=-2.299,-2.112；P＜0.05)；술후ld、7d、1개월、3개월、6개월량조간평균라안시력(t=-1.240,-1.917,-0.596,-1.394,-0.329)、등효구경(t=0.054,0.222,0.936,-0.141,0.336)화술후1、3、6개월평균각막곡솔Kl(t=-1.695,-1.492,-0.438)화산광CY(t=0.879,0.733,0.553)급술후6개월평균안압(t=-1.225)、각막곡솔K2(t=-0.727)차이균무통계학의의(P＞0.05).고도근시환자술후3개월라안시력균치시험조화대조조분별위5.14 ±0.06、5.09 ±0.07,차이구유통계학의의(t =2.517,P=0.015).량조환자간각주관증상상사；소유환자균미출현고안압급굴광도수명현회퇴현상.결론 SBK술후응용0.1％추분산납수합물적안액가이체도여불미룡적안액동양적치료효과,재술후안압안전성방면0.1％추분산납수합물적안액경우우불미룡적안액.
Objective To investigate the clinical efficacy and safty of 0.1％ bromfenac sodium hydrate ophthalmic solution in myopia and astigmatism eyes after sub-Bowman keratomileusis (SBK)Methods A case control study.Number of patients with low to moderate myopia (-6.00 D ≤ spherical equivalent ＜-2.00 D) in the test and control groups was 17 cases (32 eyes) and 20 cases (40 eyes),respectively.Number of patients with high myopia (-11.00 D ＜ spherical equivalent ＜-6.00 D) in the test and control groups was 22 cases (42 eyes) and 15 cases (26 eyes) respectively.The first day after SBK,0.1％ bromfenac sodium hydrate eye drops was administrated 2 times/day in patients in the test group and continued for 10 and 14 days in low and high myopia,respectively.In the control group,0.1％fluorometholone eve drops was used 4 times/day,then reduced gradually and continuously for 16 days.Visual acuity,computer refraction,intraocular pressure (IOP) and corneal topography examination were conducted at different postoperative period.Symptoms and related complications were recorded.Ranked data were statistically analyzed using the Wilcoxon rank sum test and quantitative data were analyzed using independent samples t-test.Results For low to moderate myopic patients,average postoperative IOP and corneal curvature K2 after one and three months in the test group were (7.84 ± 1.35) and (8.13 ± 1.75)mm Hg(1 mm Hg =0.133 kPa),and (38.66 ± 1.68) and (38.75 ± 1.45) D,respectively; in the control group,these parameters were (9.37 ± 1.28) and (9.47 ± 1.58) mm Hg and (39.56 ± 1.58),and (39.51 ± 1.50) D,respectively.All of these data in the test group were lower than those in the controlgroup,the differences were statistically significant (t =-2.299,-2.112,P ＜ 0.05).There were no significant differences (P ＜ 0.05) in postoperative uncorrected visual acuity,spherical equivalent,corneal curvature KI,astigmatism CY,IOP (after 6 months) and corneal curvature K2 (after 6 months) between the test and control group.For the high myopic patients,mean postoperative uncorrected visual acuity in the test group and control group after 3 months were 5.14 ± 0.06 and 5.09 ± 0.07,respectively.The difference was statistically significant (t =2.517,P =0.015).There were no significant differences in symptoms between these two groups (two-sided test P ＞ 0.1).High IOP and obvious myopia regression were not found in all patients.Conclusions Bromfenac sodium hydrate eye drops (0.1％) can achieve the same therapeutic effect as fluorometholone eye drops after SBK and the former is better than the later in postoperative IOP control.
